U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06834412) titled 'A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging for Targeting CXCR4 in the Clinical Staging of Hematological Tumor, and Comparing it With 18F-FDG PET/CT Imaging' on Feb. 13.
Brief Summary: This is a prospective, open-label, single-center clinical study targeting hematological malignancies. 120 patients with a confirmed by pathology of non-Hodgkin's lymphoma or myeloma were included. Qualified subjects will undergo 18F-FDG PET/CT and 68Ga-Pentixafor PET/CT examination. The aim is to To investigate whether 68Ga-pentixafor PET imaging can be used as a reliable complement to 18F-FDG PET imaging for clinical staging, treatmen...